日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The TALAPRO-3 study design: a plain language summary

TALAPRO-3 研究设计:简明语言概述

Agarwal, Neeraj; Saad, Fred; Azad, Arun A; Mateo, Joaquin; Matsubara, Nobuaki; Shore, Neal D; Chakrabarti, Jayeta; Chen, Hsiang-Chun; Lanzalone, Silvana; Niyazov, Alexander; Fizazi, Karim

Radiation Damage by Heavy Ions in Silicon and Silicon Carbide Detectors

重离子对硅和碳化硅探测器的辐射损伤

Altana, Carmen; Calcagno, Lucia; Ciampi, Caterina; La Via, Francesco; Lanzalone, Gaetano; Muoio, Annamaria; Pasquali, Gabriele; Pellegrino, Domenico; Puglia, Sebastiana; Rapisarda, Giuseppe; Tudisco, Salvatore

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

HER2阴性、携带BRCA1/2种系突变的乳腺癌患者对Talazoparib治疗反应的决定因素

Blum, Joanne L; Laird, A Douglas; Litton, Jennifer K; Rugo, Hope S; Ettl, Johannes; Hurvitz, Sara A; Martin, Miguel; Roché, Henri H; Lee, Kyung-Hun; Goodwin, Annabel; Chen, Ying; Lanzalone, Silvana; Chelliserry, Jijumon; Czibere, Akos; Hopkins, Julia F; Albacker, Lee A; Mina, Lida A

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

在亚洲国家入组的HER2阴性晚期乳腺癌且携带BRCA1/2种系突变的患者中,他拉唑帕尼与化疗的疗效比较:EMBRACA III期试验的探索性亚组分析

Lee, Kyung-Hun; Sohn, Joohyuk; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Im, Seock-Ah; Kim, Sung-Bae

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

在携带胚系 BRCA1/2 突变、HER2 阴性的晚期乳腺癌患者中,他拉唑帕尼与化疗的疗效比较:EMBRACA 试验的最终总生存期结果

Litton, J K; Hurvitz, S A; Mina, L A; Rugo, H S; Lee, K-H; Gonçalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roché, H; Im, Y-H; Eiermann, W; Quek, R G W; Usari, T; Lanzalone, S; Czibere, A; Blum, J L; Martin, M; Ettl, J

Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation

克唑替尼联合帕博利珠单抗治疗既往未接受治疗的伴有ALK易位的晚期非小细胞肺癌患者的Ib期研究

Patel, Sandip Pravin; Pakkala, Suchita; Pennell, Nathan A; Reckamp, Karen L; Lanzalone, Silvana; Polli, Anna; Tarazi, Jamal; Robert-Vizcarrondo, Francisco

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

大型多国临床试验PROFILE 1005的最终结果:克唑替尼治疗既往接受过治疗的晚期/转移性ALK阳性非小细胞肺癌患者的疗效和安全性

Blackhall, Fiona; Ross Camidge, D; Shaw, Alice T; Soria, Jean-Charles; Solomon, Benjamin J; Mok, Tony; Hirsh, Vera; Jänne, Pasi A; Shi, Yuankai; Yang, Pan-Chyr; Pas, Tommaso De; Hida, Toyoaki; Carpeño, Javier De Castro; Lanzalone, Silvana; Polli, Anna; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D; Kim, Dong-Wan

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

机制相关循环蛋白作为接受舒尼替尼治疗的不可切除肝细胞癌患者临床结果的生物标志物

Charles S Harmon, Samuel E DePrimo, Eric Raymond, Ann-Lii Cheng, Eveline Boucher, Jean-Yves Douillard, Ho Y Lim, Jun S Kim, Maria José Lechuga, Silvana Lanzalone, Xun Lin, Sandrine Faivre